Voyager Therapeutics Inc expected to post a loss of 37 cents a share - Earnings Preview

Voyager Therapeutics

07/03/2025 20:53

Voyager Therapeutics Inc VYGR.OQ VYGR.O is expected to show a fall in quarterly revenue when it reports  results on March 11 for the period ending December 31 2024

The Lexington Massachusetts-based  company is expected to report a 81.6% decrease in revenue to $16.577 million from $90.06 million a year ago, according to the mean estimate from 12 analysts, based on LSEG data.

​LSEG's mean analyst estimate for Voyager Therapeutics Inc is for a loss of 37 cents per share.

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 12 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Voyager Therapeutics Inc is $16.00​, above​ its last closing price of $4.14. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Sep. 30 2024
-0.40
-0.45
-0.16
Beat
64.7
Jun. 30 2024
-0.41
-0.41
-0.18
Beat
56
Mar. 31 2024
-0.43
-0.44
-0.20
Beat
54.5​
Dec. 31 2023
-0.16
-0.29
1.25
Beat
533.2
​​Sep. 30 2023
-0.57
-0.58
-0.59
Missed
-1.5
Jun. 30 2023
-0.57
-0.57
-0.51
Beat
10.3​
Mar. 31 2023
1.00
0.77
2.94
Beat
281
Dec. 31 2022
-0.54
-0.55
-0.61
Missed
-11.5

This summary was machine generated March 7 at 20:53 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)